DNMT3A mutations in exon 23 are associated with improved survival in AML patients treated with Azacytidine plus standard chemotherapyPetra Tschanter, Carsten Müller‐Tidow, M. Fueller et al.|Kölner Universitäts PublikationsServer (Universität zu Köln)|2015Cited by 0